Molnupinavir: How does the anti-Cavid pill arrive in France?
This drug against the coronavirus will arrive in France in December 2021.Based on molnupinavir, this is the first covid drug that can be taken orally, and this can change a lot of things.
While he announced on the new measures on the dose of recall and the health pass, the Minister of Health Olivier Véran took the opportunity to recall the arrival of the first anti-Cavid drugs for the end of 2021.Confirming the prior announcement of Emmanuel Macron, Olivier Véran referred to molnupinavir: it is a pill, which can be prescribed in December 2021 by general practitioners.
This medication will be reserved for people risking contracting serious forms of the disease.
Our video on anti-Cavid pills:
The United Kingdom was the first country where molnupinavir was available.In France, the Minister of Health Olivier Véran announced that he had ordered 50,000 doses.
The Merck pill is an antiviral, in curative
The drug is an antiviral, which means that it acts once an infection has taken place.A virus, when he contaminates the organism, replies within cells.To prevent it from hurting, it is necessary to disturb this replication cycle, and this is where antivirals come in..
In this case, the pill developed by Merck laboratories is based on molnupinavir.Originally, this drug is known for care against hepatitis C and flu.Very early in the history of coronavirus research, trials showed that molnupinavir was potentially effective against COVVI-19 disease.He first proven himself in mice, then during the human clinical trials of phase 2 and phase 3.The Merck laboratory affirms, at the end of studies, that this reduces the risk of death or hospitalization by 50 %.
Treatments will help to master the epidemic linked to the SARS-COV-2 coronavirus.
Source: Pexels
The molnupinavir inserts errors during the replication of the viral RNA of the coronavirus, making any new copy of the virus based on the disturbed RNA is less effective than previously.Of thread by needle, the drug therefore mutates the coronavirus until it dies.
What molnupinavir could change
After studying the data transmitted to it by Merck, the British health authority - where the drug was validated first in the world - had concluded that the drug turns out to be "safe and effective in reducing the risk ofhospitalization and death in people with light or moderate covid-19 and presenting an increased risk of developing serious illness.»»
This medication has several advantages, the first being that it will be trained orally.This is a first, because the previous treatments approved against the covid were inject by intravenous.Oral treatment can be administered outside the hospital context and, as soon as possible in the progression of the disease.
The British Ministry of Health specified that the drug could change things for the most vulnerable and immunocompromised people;What Olivier Véran also said in France.This is indeed the case: these patient profiles, in which the immune system is faulty, are the most at risk in the event of development of the COVVI-19 disease.For these people, the vaccine may not always be enough to boost the immune system.The risk is then that serious or long shapes reach them.An effective, risk -free drug that can be taken very soon after infection has the advantage of avoiding a severe version of the disease.
To understand everything in the coronavirus epidemic (COVVI-19)